Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Income (2016 - 2025)

Historic Operating Income for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $66.3 million.

  • Catalyst Pharmaceuticals' Operating Income rose 3016.76% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.8 million, marking a year-over-year increase of 4874.43%. This contributed to the annual value of $195.1 million for FY2024, which is 12476.62% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Operating Income stood at $66.3 million, which was up 3016.76% from $66.3 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Operating Income registered a high of $66.3 million during Q2 2025, and its lowest value of -$37.2 million during Q3 2023.
  • Its 5-year average for Operating Income is $33.3 million, with a median of $30.8 million in 2022.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Operating Income plummeted by 24814.76% in 2023 and then surged by 23689.63% in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Operating Income stood at $12.7 million in 2021, then soared by 141.73% to $30.8 million in 2022, then surged by 35.36% to $41.7 million in 2023, then surged by 50.73% to $62.8 million in 2024, then grew by 5.45% to $66.3 million in 2025.
  • Its last three reported values are $66.3 million in Q3 2025, $66.3 million for Q2 2025, and $63.4 million during Q1 2025.